Our findings demonstrate unexpected efficacy of a novel sodium channel blocker in Dravet syndrome and suggest a potential mechanism involving a secondary change in NaV1.6. This evidence concerns the gene SCN8A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.